Table 1.
distribution of pathologic features and molecular phenotypes of general population by age groups
| Histological/phenotypes characteristics | Number of patients (%) | <40 | (40-54) | ≥55 | P-Value | |
|---|---|---|---|---|---|---|
| Histological types | Ductal | 877 (79.4%) | 154 (81.9%) | 402 (80.7%) | 321 (76.6%) | 0.011 |
| Lobular | 181 (16.4%) | 20 (10.6%) | 82 (16.5%) | 79 (18.9%) | ||
| Other | 47 (4.2%) | 14 (7.4%) | 14 (2.8%) | 19 (4.5%) | ||
| Inflammatory breast cancer | IBC | 47 (5.3%) | 6 (3.8%) | 21 (5.4%) | 20 (6%) | 0.616 |
| NIBC | 834 (94.7%) | 150 (96.2) | 370 (94.6 %) | 176 (%) | ||
| TNM staging | pT1 | 114 (13%) | 19 (12.2%) | 51 (13%) | 44 (13%) | 0.768 |
| pT2 | 449 (51%) | 75 (48.5%) | 198 (50.4%) | 176 (52.4%) | ||
| pT3 | 142 (16%) | 32 (20.6%) | 61 (15.5%) | 49 (14.6%) | ||
| pT4 | 179 (20%) | 29 (18.7%) | 83 (21.1%) | 67 (20%) | ||
| M1 at the moment of diagnostic | 82 (7.2%) | 15 (7.6%) | 38 (7.4%) | 29 (6.6%) | 0.007 | |
| Nodal status | N- | 350 (35.3%) | 61 (36.1%) | 143 (32.4%) | 146 (38.3%) | 0.206 |
| N+ | 641 (64.7%) | 108 (63.9%) | 298 (67.6%) | 235 (61.7%) | ||
| SBR grade | I | 38 (3.6%) | 10 (5.6%) | 14 (2.9%) | 14 (3.5%) | 0.269 |
| II | 610 (57.5%) | 98 (54.5%) | 283 (59.2%) | 229 (57%) | ||
| III | 412 (38.9%) | 72 (40%) | 181 (37.9%) | 159 (39.5%) | ||
| Hormone receptors status | HR- | 417 (39.1%) | 60 (33.1%) | 182 (37.7%) | 175 (43.5%) | 0.040 |
| HR+ | 649 (60.9%) | 121 (66.9%) | 301 (62.3%) | 227 (56.5%) | ||
| HER2 status | HER2- | 714 (67.6%) | 123 (68%) | 313 (65.5%) | 278 (69.8%) | 0.358 |
| HER2+ | 343 (32.4%) | 58 (32%) | 165 (34.5%) | 120 (30.2%) | ||
| Ki 67 status | Ki 67 <14 | 230 (40%) | 41 (45.1%) | 93 (45.8%) | 96 (45.1%) | 0.986 |
| Ki 67 ≥ 14 | 277 (60%) | 50 (54.9%) | 110 (54.2%) | 117 (54.9%) | ||
| Molecular phenotypes | Luminal A | 337 (31.6%) | 69 (38.1%) | 156 (32.2%) | 112 (27.9%) | 0.025 |
| Luminal B | 313 (29.4%) | 52 (28.7%) | 146 (30.2%) | 115 (28.7%) | ||
| HER2+ | 130 (12%) | 18 (9.9%) | 68 (14%) | 44 (11%) | ||
| TNBC | 286 (27%) | 42 (23.2%) | 114 (23.6%) | 130 (32.4%) |